Naloxone, packaged with instructions, is one of the items given out by the Baltimore Harm Reduction Coalition outreach workers.
The U.S. Food and Drug Administration has approved the prescription-free sale of the second opioid overdose reversal drug, its manufacturer Harm Reduction Therapeutics said on Friday.
The approval of the drug, called RiVive, will provide patients with another over-the-counter option in the United States, where drug-related overdose deaths surpassed 100,000 in 2021.
Harm Reduction said it anticipates that RiVive will be available early next year, primarily to harm-reduction organizations and state governments.
Harm Reduction Therapeutics has partnered with contract drug manufacturer Catalent Inc to manufacture RiVive.
Persons:
drugmaker, Michael Hufford, BioSolutions
Organizations:
Reduction Coalition, U.S . Food, Drug Administration, Therapeutics, Harm, Catalent Inc
Locations:
Baltimore, U.S, United States